Close menu




March 9th, 2023 | 10:58 CET

Innovations for millions: Volkswagen, JinkoSolar, Meta Materials

  • Technology
  • metamaterials
  • Innovations
Photo credits: pixabay.com

If a company is ahead of the competition, its business runs all by itself. Large companies invest billions to set themselves apart from the market. But the structure of corporations too often puts the brakes on visionary projects. Fortunately, there are smaller companies that are wholly committed to new technology. We present three companies and explain which could soon become the focus of the big players.

time to read: 3 minutes | Author: Nico Popp
ISIN: VOLKSWAGEN AG ST O.N. | DE0007664005 , JINKOSOLAR ADR/4 DL-00002 | US47759T1007 , Meta Materials Inc. | US59134N1046

Table of contents:


    Volkswagen: Thousands of patents, but where is the bright idea?

    Thanks to good business and an early focus on electromobility and sustainability, Volkswagen's profits are bubbling up - most recently, surpluses climbed by around 25%. Volkswagen now invests around EUR 18 billion in innovations every year. In October 2020, Volkswagen held almost 15,000 patents. But what makes cars better bit by bit does not necessarily initiate a technological revolution. When it comes to attacking electric top dogs like Tesla or BYD, Volkswagen has, so far, left a lot to be desired.

    JinkoSolar: Even technology leaders have to be innovative

    JinkoSolar is also considered particularly innovative. The Chinese specialist for photovoltaic systems impresses above all with low prices and high quality. Years ago, modules from Germany were still considered to be of high quality. But the Chinese first copied and then got better and better. Today, JinkoSolar is well-positioned to survive in the competitive market for PV modules. Analysts also see it that way: On average, analysts see around 19% price potential measured against the current share price. As early as 2022, JinkoSolar benefited from the increased demand for PV modules and significantly increased profits by 158%. However, observers also have growing competition and cost pressure at the back of their minds at JinkoSolar. Only if the Company remains innovative can it maintain its current market position.

    The examples of Volkswagen and JinkoSolar show that even global market leaders and proven giant corporations must stay on the ball to maintain their market position. Above all, technological revolutions are relatively rare in corporate structures - many of VW's patents probably still relate to classic passenger cars, as we have known them for decades. This is another reason why large industrial companies have to buy innovative startups occasionally or enter into certain cooperative ventures. A sought-after cooperation partner is Meta Materials, a company listed on Nasdaq.

    Meta Materials as a jack-of-all-trades: E-cars, medical technology, solar cells

    The US company works with Boeing, Samsung, Airbus, Mazda and Covestro, among others. Meta Materials' focus is on ultra-thin coatings. This so-called metamaterial has physical properties that do not exist in nature. They can be used, for example, to create ultra-thin 5G antennas in window panes, reflectors for mobile phone signals in house facades and windows, or invisible displays in car windshields. Metamaterials can also be used in battery technology: For example, the Company of the same name wants to use ultra-thin films coated with copper or aluminium to save weight in lithium-ion batteries.

    Other projects that Meta Materials is working on revolve around coatings for better vision, solutions for data glasses and augmented reality or medical applications such as sensors and diagnostic devices. In total, Meta Materials holds 292 patents. The share is also considered a future investment. In the summer of 2021, the value multiplied within a few days in the wake of overbearing tech speculation and a short squeeze. Since then, the value has been trending sideways, although the Company can constantly report new developments. The share is a classic growth stock - the market is still cautious concerning possible commercialization. However, as soon as the sentiment around growth stocks changes, Meta Materials, a well-known Nasdaq stock, should also pick up again. Even a pause in interest rates by the major central banks could boost growth stocks again.

    Volkswagen also relies on augmented reality Source: Volkswagen AG

    Tailwinds for companies like Meta Materials could also come from established industrial companies. The tech stock's business could be a good fit for companies in the chemical sector, for example, which are looking to divest energy-intensive areas. Companies like VW or JinkoSolar depend on innovations to maintain their market position. Even if growth stocks are not in focus at the moment, they have perspective. Meta Materials touches numerous industries and offers something new with its technology. Sometimes it takes time for innovations to become established. It can be worthwhile for investors, in particular, to get a foot in the door with Meta Materials or at least to follow the stock closely.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by André Will-Laudien on April 24th, 2024 | 07:00 CEST

    Takeover rumors for biotech shares: BioNTech, Formycon, Cardiol Therapeutics and Novo Nordisk in focus

    • Biotechnology
    • Pharma
    • Innovations
    • Cancer

    The biotech sector has significantly lagged behind the performance of artificial intelligence and high-tech this year. This is due to high inflation, which in turn has made an imminent interest rate cut unlikely. Nevertheless, Germany's economic conditions are deteriorating dramatically, particularly due to the ongoing geopolitical conflicts. It should, therefore, come as no surprise if the ECB announces an "emergency interest rate cut" in the summer. That would then be the starting signal for a major reshuffle out of the best performers of recent months and into the long-neglected biotech segment. We have selected a few interesting stocks.

    Read

    Commented by André Will-Laudien on April 23rd, 2024 | 07:45 CEST

    Attention: DAX dividends! Car stocks pay out: Mercedes-Benz, MS Industrie, VW and BMW

    • Technology
    • hightech
    • Automotive
    • Electromobility

    The DAX 40 index has gone into reverse gear in recent weeks. In addition to the high-tech and artificial intelligence sectors, the multi-month bull market also included defense stocks in the interim phase. There is no real reason to celebrate among automotive stocks, as an expected decline in GDP also means reduced household budgets. This translates to fewer new vehicle sales, with many electric vehicles produced in bulk occupying important showroom space from dealers for months. The pain is increasing, and those looking to sell vehicles find themselves in ruinous discount battles with cheap Chinese imports. However, there appears to be a glimmer of hope on the horizon: interest rate cuts! They are expected in the second half of the year. We analyze the current situation.

    Read

    Commented by Fabian Lorenz on April 23rd, 2024 | 07:00 CEST

    TAKEOVER FEVER for biotech shares! Evotec, Bayer, Vidac Pharma - Who will follow Morphosys?

    • Biotechnology
    • Pharma
    • Innovations
    • Cancer

    There is takeover fever in the biotech sector. Genmab recently announced the acquisition of ProfoundBio, the US biotech company developing ovarian and endometrial cancer drugs, for USD 1.8 billion. With Morphosys, the takeover carousel is also turning in Germany. Who is the next candidate? Evotec is often mentioned. Due to unauthorized insider trading, the biotech company's shares have come under fire this year and offer an interesting entry opportunity. Vidac Pharma also impresses operationally. The Company's new approach has the potential to revolutionize cancer treatment. The study results of the past few months are very promising. Bayer shares surprised investors yesterday as one of the day's winners in the DAX. Is the Leverkusen-based company's stock about to take off?

    Read